Recent publications have produced some new estimates of the incidence of pregnancy-related venous thromboembolic disease, and have found increasing evidence of an association between inherited thrombophilias and pregnancy complications and fetal loss. The balance of benefit and risk of thromboprophylaxis remains to be evaluated, and studies are needed to provide a sound basis for clinical practice. Curr Opin
Introduction
Thromboembolic disease (TED) is the greatest single cause of maternal death in developed countries [1, 2] . In the UK, the latest report of the Con®dential Enquiry into Maternal Deaths (Department of Health, 1998) [3] , covering the years 1994±1996, found that there were 46 deaths from this cause, an increase from 35 in the previous report [4] . Some of this increase can be attributed to a better ascertainment of cases, but it is clear that death from TED is not declining and remains a serious concern, despite clinicians' efforts to provide thromboprophylaxis to women at risk. The majority of thromboembolic events in pregnancy are not fatal, but in those cases TED may be responsible for considerable long-term morbidity. There is evidence that thromboembolic events during pregnancy produce more severe and long-lasting subsequent morbidity than events outside pregnancy [5, 6] .
Despite the widely recognized importance of TED in pregnancy as a cause of maternal mortality and morbidity, much remains to be discovered about its epidemiology and causes, and the effectiveness of thromboprophylaxis. Many reviews of TED in pregnancy and thromboprophylaxis have been published in recent years [7,8 . ,9 . ], but there is an urgent need for further research in many areas. Research priorities are discussed in a later section.
Incidence of pregnancy-associated thromboembolic disease TED in association with pregnancy is known to be rare, but only a few studies have estimated its overall incidence or the risk for any particular group of women. Two large studies [10 . ,11 . ] have recently estimated the overall incidence of TED in populations in Sweden and the USA.
Lindqvist et al. [10 . ] used the Swedish national registries of births and hospitalizations to investigate the number of objectively con®rmed deep vein thromboses and pulmonary emboli associated with pregnancy that occurred between 1990 and 1993. The study's methodology allowed the researchers to avoid a problem encountered by some earlier studies [12]: many episodes of TED were not recorded as being associated with pregnancy because postpartum episodes were treated in medical wards and not coded as pregnancy-related in routinely collected data. Therefore, routinely-collected data may underestimate the true incidence of pregnancyrelated TED. Use of the national registers in the new study allowed the identi®cation of all thromboembolic events occurring between 240 days before delivery and 6 weeks postpartum, regardless of how they were classi-®ed, hence avoiding the problem of misclassi®cation. The overall incidence of venous thromboembolic events was 1.3 per 1000 deliveries, considerably higher than the 0.86 per 1000 deliveries reported by McColl et al. [13] , and other earlier ®gures [14] . Of 608 thromboses occurring in ®rst pregnancies, just over half (308) occurred antepartum and half (300) postpartum. The daily risk of TED was therefore highest in the postpartum period, con®rming the ®ndings of earlier studies. In the other recent study, Gherman et al. [11] found only 165 episodes of pregnancy-related TED among 268 525 deliveries between 1978 and 1996, a rate of 0.6 per 1000 deliveries. Again, only objectively con®rmed events were included. Almost 75% of the events occurred in the antepartum period, although the majority (60%) of pulmonary emboli occurred postpartum and were strongly associated with Caesarean section. The differences between these two studies may result from differences in the populations in the prevalence of risk factors, for example, different frequencies of thrombophilias or differences in methodology.
Ray and Chan [15 . ] summarized the available estimates of the incidence of TED during pregnancy and the postpartum period. Combining data from nine studies, they found that 65.5% of thromboembolic events arose antenatally, and 34.5% postpartum. The estimated daily risk was nearly four times higher in the postpartum period. However, many of the studies included in Ray and Chan's review suffer from the problem of misclassi®cation of postnatal thromboembolic events noted above, and hence are likely to underestimate their incidence. This study also found that 82.2% [95% con®dence interval (CI) 75.1±87.5] of pregnancy-related events affected the left leg, a very similar value to that found in the study by Gherman et al. [11 . ] (81.9%). Greer [9 . ] suggested that the predominance of thromboses on the left is caused by compression of the left iliac vein by the right iliac and ovarian arteries.
Risk factors for thromboembolic disease
TED is multicausal [16] , and many different factors may contribute to an individual's probability of developing it during pregnancy. The main risk factors for TED in association with pregnancy are those that promote venous stasis and hypercoagulability: thrombophilias, operative delivery, obesity, immobility, higher parity and greater maternal age (see reviews [7,8 . ,9 . ] for more details).
Although the main risk factors have been established, the risks for women in these groups are less well known. For women delivered by Caesarean section, data from Scotland [11 . ] suggested that the incidence of TED may be higher after emergency than after elective operations, but the study was likely to underestimate the true risk because of the misclassi®cation of pregnancy-related episodes of TED. As Caesarean section now accounts for up to 20% of deliveries in some counties, it is probably the commonest risk factor for TED. Better estimates of the risks of TED after operative delivery may help clinicians to target thromboprophylaxis more appropriately.
The association of a range of inherited and acquired thrombophilias, including antithrombin III de®ciency, protein C de®ciency, protein S de®ciency, activated protein C (APC) resistance (usually resulting from the factor V Leiden mutation), antiphospholipid antibody syndrome and hyperhomocysteinaemia, with TED in pregnancy has been well documented [13] . Recently, Grandone et al. [17 . ] reported associations of two more recently discovered inherited thrombophilias with pregnancy-related TED. The prothrombin G20210A mutation was strongly associated with TED [odds ratio (OR) 10.2, 95% CI 4.0±25.9], but the association with the methylenetetrahydrofolate reductase C677T mutation appeared to be less strong (OR 2.1, 95% CI 1.0±4.5). The numbers in this study, as in most similar investigations, were small. However, the large number of women who had these mutations (31% and 29%, respectively, of the women with thromboses) suggests that these genotypes may underlie a substantial proportion of cases of venous TED.
The risks of TED for carriers of thrombophilias have not yet been well quanti®ed. Studies have either taken a case±control approach and studied the incidence of thrombophilia among women who have experienced TED and controls who have not (which does not give an estimate of the absolute risk), or have been too small to give more than an imprecise estimate [18]. In addition, some studies may suffer from selection bias; women may have been included in a study because they or a close relative had had a thrombosis. Thus they may have been at higher risk of TED than women with thrombophilias who were from families where no thromboses had occurred. There is also the complication for some thrombophilias that the risk of TED may be higher for homozygous carriers of the gene than heterozygous carriers. The risk of TED among carriers of the factor V Leiden mutation was estimated by a recent cohort study by Lindqvist et al. [19 . . ], involving 2480 women. The numbers of thromboembolic events were small, but the incidence was 1.1%, considerably higher than the 1 in 400±500 risk estimated by McColl et al. [13] . Further cohort studies are necessary to identify the risks of TED more precisely for factor V Leiden and other thrombophilias.
Thromboprophylaxis
Heparin is the most commonly used drug for thromboprophylaxis during pregnancy because it does not cross the placenta and does not affect the developing fetus. However, heparin has a risk of side-effects: heparininduced thrombocytopenia, bleeding, osteoporosis, allergic reactions, and wound complications when used after Caesarean section [20] . There is therefore a balance of risks and bene®ts to heparin thromboprophylaxis; the therapy may be bene®cial in reducing TED, but it has a risk of harmful effects. Low molecular weight heparins are now probably most commonly used, because they only need to be injected once rather than twice a day, and are thought to be associated with fewer complications [21] . Sanson et al. [22 . ] recently summarized reports of the use of low molecular weight heparin during pregnancy. They found an overall rate of thromboembolic complications of 0.6% (95% CI 0.1± 1.8%), and only one case of symptomatic osteoporosis in 486 women. The rate of adverse fetal or infant outcomes was similar to that found in the general population. These results led the authors to conclude that low molecular weight heparin is suitable for use during pregnancy. However, the studies summarized were not randomized comparisons, but simply observations with no control group, and therefore do not give an accurate estimate of whether the treatment either increases the risk of adverse outcomes or reduces the risk of TED.
The risks and bene®ts of thromboprophylaxis during pregnancy, and therefore which groups of women would bene®t from receiving it, are currently unknown, because no suf®ciently large randomized controlled trials (RCTs) have evaluated the therapy. In fact, only a very limited number of small RCTs have been carried out [23±27]. None of these have been large enough to assess the effects of thromboprophylaxis on rare outcomes such as TED or side effects of heparin. With this almost complete lack of high quality information about the safety and effectiveness of thromboprophylaxis in pregnancy, recommendations for practice cannot be evidence-based. Guidelines for practice have been produced [28] , but they are based only on expert opinion, and large-scale RCTs are necessary to assess accurately the risks and bene®ts of thromboprophylaxis. The need for such large studies has been recognized for many years [8 . ,29], but so far none have been conducted. Until the necessary evidence is produced, the concern remains that many women may be exposed to the hazards of heparin thromboprophylaxis without appreciable bene®t.
Current randomized controlled trials of thromboprophylaxis: the APPLE and PEACH studies
The Perinatal Trials Service is currently running pilot studies for two large-scale, multicentre, RCTs of thromboprophylaxis in pregnancy. The ®rst of these, the APPLE study, is concerned with antenatal prophylaxis. All women considered at increased risk of TED are eligible to participate; they are recruited antenatally and are randomly allocated to receive daily injections either of low molecular weight heparin or a matching placebo from entry to the study until 6 weeks after delivery, although the study drug can be stopped and heparin substituted if the clinician feels that this is necessary. For example, many clinicians prefer to give heparin after delivery. The second study, PEACH, evaluates prophylaxis after Caesarean section. All women who are delivered by Caesarean section are eligible to participate in the trial. They are randomly assigned to receive a once daily subcutaneous injection of either low molecular weight heparin or placebo, from delivery until discharge from hospital or for a maximum of 14 days.
More information about these studies can be obtained from the Perinatal Trials Service, and the study protocols are available from the National Perinatal Epidemiology Unit's website (www.npeu.ox.ac.uk).
Inherited thrombophilias and complications of pregnancy
Evidence has emerged in recent years suggesting a link between thrombophilic conditions and complications of pregnancy, including fetal loss, pre-eclampsia and intrauterine growth restriction. Acquired thrombophilias were ®rst implicated in pregnancy complications, but an increasing body of evidence has discovered similar effects with inherited conditions. For more details of this literature see the reviews by Greer [9 . ] and Blumenfeld and Brenner [30 . ]. Recent studies are summarized in Tables 1 and 2. Two cohort studies have examined the effects of the factor V Leiden mutation. Lindqvist et al. [19 . . ] carried out a prospective cohort study. The women were recruited in early pregnancy and their factor V Leiden status was determined. The prevalence of the mutation was 11%. The rate of pregnancy complications, including fetal loss, pre-eclampsia and intrauterine growth retardation was not signi®cantly different between APCresistant and non-APC-resistant women, but the rate of thromboembolic events was approximately eight times higher in carriers of the mutation. There was also a lower rate of intrapartum haemorrhage among APC-resistant women (3.7 versus 7.9%; RR 0.49, 95% CI 0.26±0.91), and a smaller volume of blood loss, providing some possible support for the same group's earlier suggestion that the factor V Leiden mutation may afford some protection against blood loss during delivery [37] . In contrast, a retrospective cohort study including 228 carriers with 654 pregnancies and 121 non-carrier relatives with 352 pregnancies [31 . . ] found a greater risk of fetal loss among carriers than non-carriers of the mutation (OR 2.12, 95% CI 1.35±3.33). There was also a suggestion that the risk is greater for homozygous than heterozygous carriers (OR 2.01, 95% CI 0.94±4.32), although the number of events among homozygous women was small (nine out of 38 pregnancies).
Two other recent case±control studies have found an association between fetal loss and thrombophilias [33 . ,34 . . ]. Both found that women who had experienced fetal loss were more likely to have a thrombophilia compared with controls, although the prevalence differed between the studies, possibly as a result of different de®nitions ( Despite small numbers, differences were apparent for all of the thrombophilias studied, including factor V Leiden, methylenetetrahydrofolate reductase mutation, prothrombin mutation, de®ciency of protein C, protein S or antithrombin III (considered together), and anticardiolipin antibodies.
The suggested mechanism for the involvement of thrombophilias in pregnancy complications and fetal loss is that thromboses in the placenta lead to the various adverse outcomes that are observed. Placental infarctions have been observed in aborted fetuses of factor V Leiden carriers [38, 39] , lending support to this idea. Meinardi et al. [31 . . ] suggest that fetal loss may be caused by placental thromboses on either the fetal or maternal side of the placental interface. This may explain the higher rate of loss in homozygous mothers in their study, as all fetuses of homozygous mothers will carry the thrombophilic mutation, compared with 50% of fetuses of heterozygous mothers. A further implication of this suggestion is that the genotype of the father may also be important; a father who carries the mutation may pass it to his offspring, so a heterozygous fetus may result from a carrier father and non-carrier mother. Such fetuses may have an increased risk of adverse outcomes. There are few data on the thrombophilia status of fathers. In their case±control study, Gris et al. [34 . . ] reported no difference in the prevalence of thrombophilias between partners of women with late fetal loss and those without (5.2 versus 4.7%), although the small numbers limit the power of the test. A more stringent test would be provided by recording the outcome of pregnancy in a group of women whose partners were carriers of thrombophilias, compared with a control group of women with non-carrier partners.
This mechanism of disease suggests that affected women might bene®t from therapy during pregnancy to correct their coagulation abnormality. For acquired thrombophilic conditions, some evidence has emerged that aspirin and heparin are bene®cial in preventing miscarriage and fetal loss [40, 41] . However, for inherited thrombophilias no possible therapies, such as anticoagulants or folic acid supplementation to reduce homocysteine levels, have been evaluated in RCT. A preliminary observational study [42] of the effects of low molecular weight heparin and aspirin for women with inherited thrombophilias has recently been published.
The study concluded that heparin may have a favourable effect on pregnancy outcome, and suggested that RCT should be conducted. Nelson-Piercy [43 . ] discusses the desirability of testing women with pregnancy complications for thrombophilias. At present, the risks of thromboses and adverse pregnancy outcomes are unknown, and possible interventions have not been evaluated. Thrombophilia screening may therefore lead to unnecessary exposure of women to potentially harmful therapies.
Research priorities
Further studies are needed on several aspects of TED to provide the sound information on which guidelines for clinical practice can be based.
More studies are needed on the risks of TED in women with various risk factors, including inherited thrombophilias and emergency and elective Caesarean section. Several studies have demonstrated that women with multiple risk factors are at increased risk of TED, and it would be useful to investigate how the risk increases when more than one risk factor is present; are the risks additive, or is there an interaction between different risk factors?
The risk of complications of pregnancy for women with thrombophilias also need to be quanti®ed, and the possible involvement of the fetal genotype in causing complications warrants investigation.
The questions of the effectiveness of thromboprophylaxis and the risk of harmful effects of this therapy need investigation to provide sound evidence on which to base clinical practice. Large, multicentre RCT are necessary because of the rarity of thromboembolic outcomes and the small number of women who could be recruited by each participating centre. It is intended that the current pilot studies being run by the Perinatal Trials Service will lead to full-scale trials of thromboprophylaxis with low-molecular weight heparin. These trials may be the best opportunity to conduct a rigorous evaluation of this therapy in the near future.
Conclusion
There is still no high-quality evidence from RCT on which to base decisions about prophylaxis for venous TED. Accurate estimates are needed of the risks of TED for women with various risk factors, as well as data on the effectiveness and safety of methods of thromboprophylaxis. Inherited and acquired thrombophilias may play an important role in a range of pregnancy complications as well as TED, raising the possibility that interventions to prevent blood clots may help to prevent other conditions that cause signi®cant maternal and neonatal morbidity. . 15 Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999; 54:265±271. A meta-analysis of observational data on the incidence of TED in pregnancy, summarising results from 16 studies, although not including either of the recent studies (references 10 and 11). Despite the problems of meta-analysis of observational data, this study provides a useful overview of available estimates of the risks of TED. Thrombosis and pregnancy in congenital deficiencies an AT III, protein C or protein S deficiency: study of 78 women. Thromb Haemost 1990; 63:319± 320.
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19 Lindqvist PG, Svenson PJ, Marsaal K, Grennert L, Luterkort M, Dahlback B. Activated protein C resistance (FV: Q506) and pregnancy. Thromb Haemost 1999; 81:532±537. Prospective cohort study which found only a small and non-significant increase in pregnancy complications in women with Factor V Leiden (11.1% v 9.8%). This failure to confirm a result which has been established primarily by case-control studies (which are more open to bias than cohort studies) may cast some doubt on the association, and should stimulate further cohort studies. 
